Joseph Sokhn, MD
Hematology & Oncology · Chesterfield, MONPI 1912188426
Payments from drug & device makers
Across 168 payments — averaging $156.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$12K
- Pfizer$6K
- Novartis$5K
- Seagen Inc.$1K
- E.r. Squibb & Sons, L.L.C.$211
- Daiichi Sankyo Inc.$203
- plus $2K from 33 others
What the payments were for
- Consulting fees$1,25030%
- Food & beverage$2,82068%
- Education$692%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 15 | $12,318 |
| Pfizer | 30 | $6,051 |
| Novartis | 22 | $4,558 |
| Seagen Inc. | 1 | $1,250 |
| E.r. Squibb & Sons, L.L.C. | 12 | $211 |
| Daiichi Sankyo Inc. | 9 | $203 |
| Bristol Myers Squibb | 11 | $202 |
| AstraZeneca | 8 | $180 |
| Genentech USA, Inc. | 6 | $129 |
| Medtronic | 1 | $122 |
| Merck | 6 | $122 |
| Eisai Inc. | 5 | $105 |
| GSK | 3 | $63 |
| EMD Serono, Inc. | 3 | $61 |
| Astellas Pharma US Inc | 3 | $56 |
| Servier Pharmaceuticals LLC | 3 | $56 |
| Johnson & Johnson | 3 | $54 |
| Regeneron Healthcare Solutions, Inc. | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Incyte Corporation | 2 | $36 |
| Bayer | 2 | $35 |
| Amgen | 1 | $25 |
| Tersera Therapeutics LLC | 1 | $24 |
| Tactile Systems Technology Inc | 1 | $22 |
| Gilead | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Sanofi | 1 | $21 |
| Fennec Pharmaceuticals, Inc. | 2 | $20 |
| AVEO Pharmaceuticals, Inc. | 1 | $19 |
| Karyopharm Therapeutics Inc. | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Pharmacosmos Therapeutics Inc. | 1 | $16 |
| Secura Bio, Inc. | 1 | $16 |
| Dova Pharmaceuticals | 1 | $15 |
| Array Biopharma Inc | 1 | $15 |
| Stemline Therapeutics Inc. | 1 | $14 |
| Puma Biotechnology, Inc. | 1 | $14 |
| CTI Biopharma Corp. | 1 | $13 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PADCEV$1,250
- OSTEOCOOL RF ABLATION$122
How this compares
$26,224 in reported general payments places this provider in the 70th percentile of 211 hematology & oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 35 | $887,023 |
| RevlimidLenalidomide | 34 | $687,355 |
| LynparzaOlaparib | 14 | $227,838 |
| VerzenioAbemaciclib | 12 | $212,860 |
| JakafiRuxolitinib Phosphate | 12 | $210,878 |
| AlecensaAlectinib Hcl | 13 | $163,805 |
| KisqaliRibociclib Succinate | 11 | $155,330 |
| Lenalidomide | 13 | $125,678 |
| EliquisApixaban | 110 | $98,489 |
| Abiraterone Acetate | 11 | $65,865 |
| XareltoRivaroxaban | 17 | $21,912 |
| Enoxaparin Sodium | 20 | $6,310 |
| Ondansetron Hcl | 70 | $3,605 |
| Anastrozole | 206 | $3,587 |
| Hydroxyurea | 111 | $1,615 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $202 | $687,35534 claims |
| AstraZenecaLynparza | $180 | $227,83814 claims |
| Incyte CorporationJakafi | $36 | $210,87812 claims |
| Genentech USA, Inc.Alecensa | $129 | $163,80513 claims |
| NovartisKisqali | $4,558 | $155,33011 claims |
| PfizerEliquis | $6,051 | $98,489110 claims |
| Johnson & JohnsonXarelto | $54 | $21,91217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 211 hematology & oncology providers in Missouri.
Other hematology & oncology in Chesterfield
- Donald BusiekChesterfield$26K
- Stephanie GraffKansas City$6.2M
- Suman KambhampatiKansas City$4.9M
- Geoffrey UySaint Louis$4.1M
- Jaswinder SinghKansas City$3.9M
- Mark FeslerSaint Louis$2M
- James MosleyCape Girardeau$1.7M
- Shahzad RazaKansas City$1.7M
- Gerhard HildebrandtColumbia$1.6M
- David SchlossmanColumbia$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.